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ABSTRACT
Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in alcohol and opiate
addiction, but its efficacy and the mechanisms underpinning its clinical usefulness are not well characterized. In the
current study, we examined the effects of 50-mg naltrexone compared with placebo on neural network changes asso-
ciated with substance dependence in 21 alcohol and 36 poly-drug-dependent individuals compared with 36 healthy
volunteers. Graph theoretic and network-based statistical analysis of resting-state functional magnetic resonance im-
aging (MRI) data revealed that alcohol-dependent subjects had reduced functional connectivity of a dispersed network
compared with both poly-drug-dependent and healthy subjects. Higher local efficiency was observed in both patient
groups, indicating clustered and segregated network topology and information processing. Naltrexone normalized
heightened local efficiency of the neural network in alcohol-dependent individuals, to the same levels as healthy vol-
unteers. Naltrexone failed to have an effect on the local efficiency in abstinent poly-substance-dependent individuals.
Across groups, local efficiency was associated with substance, but no alcohol exposure implicating local efficiency as
a potential premorbid risk factor in alcohol use disorders that can be ameliorated by naltrexone. These findings suggest
one possible mechanism for the clinical effects of naltrexone, namely, the amelioration of disrupted network topology.
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INTRODUCTION
Substance use disorders are complex, multifaceted disor-
ders often characterized by cycles of intoxication, with-
drawal and craving, propagating substance-seeking
behaviours that persist despite often-severe negative con-
sequences. The social, health and economic costs of sub-
stance dependence (SD) are high (Nutt et al. 2010); yet
the universal efficacy of currently available treatments
is limited, and the mechanisms of action of such treat-
ments are poorly understood (Sturgess et al. 2011;
Tiffany et al. 2012). Naltrexone, an opioid receptor
antagonist targeting particularly the mu-opioid receptor
(MOR) subtype (Verebey & Mule 1975; Schmidt et al.
1985), has been shown in randomized controlled trials
to be effective in alcohol dependence (AD) but may be
more effective in some individuals or subgroups and not
others (Streeton & Whelan 2001) (Anton 2008; Sturgess
et al. 2011). The current study aims to examine the
effects of naltrexone on the neural network changes
associated with SD, specifically in poly-drug SD and AD.
Alcohol, like some other drugs of abuse, increases
mesolimbic dopamine (DA) release in rodents and
humans (Boileau et al. 2003), one mechanism by which
it exerts its primary reinforcing effects (Dichiara &
Imperato 1988; Everitt, Dickinson, & Robbins 2001).
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Activation and inhibition of the MOR in the ventral
tegmental area regulates basal dopamine release in the
nucleus accumbens (ventral striatum) (Spanagel, Herz,
& Shippenberg 1992). MOR blockade in the ventral
tegmental area inhibits dopamine release following alco-
hol intake and opioid antagonists reduce alcohol intake
in rodents (Mitchell et al. 2009). Consistent with this pre-
clinical literature, naltrexone has been shown to have a
small-to-moderate effect size in reducing alcohol use in
some (Garbutt et al. 1999; Bouza et al. 2004) but not
all studies (Krystal et al. 2001). In heroin dependence,
naltrexone blocks the physiological and psychological
effects of heroin (Navaratnam et al. 1994; Brewer
2002; Brewer & Streel 2010), preventing relapse, partic-
ularly in the early detoxification phase (Foster, Brewer, &
Steele 2003). Thus, while substantive literature impli-
cates naltrexone as an effective treatment for opiate
dependence, there are still gaps in our understanding of
its efficacy and mechanisms in individuals with AD.
Although the focus for pharmacological interventions
has been on the mesolimbic DA system (Dichiara &
Imperato 1988; Wise 1988; Everitt et al. 2001), down-
stream neural adaptations following drug use and depen-
dence also implicate a range of other cortical and
subcortical regions in drug seeking (Volkow & Fowler
2000), suggesting subsequent larger scale network disor-
ganization. Neural network organization can be exam-
ined based on synchronization of intrinsic fluctuations
in neural activity during rest, referred to as functional
connectivity. Indeed, aberrant resting-state functional
connectivity across the brain has been demonstrated in
heroin (Liu et al. 2010; Yuan et al. 2010; Jiang et al.
2013b), cocaine (Gu et al. 2010; Kelly et al. 2011;
Konova et al. 2013) and alcohol (Weiland et al. 2014)
use disorders. Investigation of these functional properties
of the brain may further our understanding of the mech-
anisms underlying the relapse prevention effects of
naltrexone.
Properties of functional brain networks can be math-
ematically captured using graph theory analysis. This
analysis method identifies and characterizes the topolog-
ical organization of brain networks as a whole (Bullmore
& Sporns 2009; He & Evans 2010), rather than based on
a regional approach. Mathematical characteristics of the
entire network can be obtained, which moves away from
examining specific regions and considers the brain a sin-
gle functioning network. In this paper, we focus on net-
work efficiency, which is indicated by the two basic
network properties, clustering coefficient and path length
(Watts & Strogatz 1998; He & Evans 2010). A clustering
coefficient describes the number of all neighbouring con-
nections for each region in a network (node) as a func-
tion of the total possible number of connections. Thus,
it represents a measure of the local efficiency of a
network. Path length describes the average number of
connections needed for any two nodes to link, so in-
versely indicating global efficiency. These two properties
(local and global efficiency) can be used to categorize net-
works into regular, random or small world (He & Evans
2010), describing both specialized and diffuse informa-
tion processing systems.
While limited, previous graph theory analyses of SD
have revealed that heroin-dependent individuals have
distorted topological neural network properties in the
form of more variable local interconnectivity (Yuan
et al. 2010) and a shift to a more random network (Jiang
et al. 2013b). A small sample of cocaine-dependent indi-
viduals show reduced local efficiency (Wang et al.
2015). However, the opposite pattern has been demon-
strated in nicotine dependence, of enhanced local effi-
ciency and reduced global efficiency (Lin et al. 2015).
Furthermore, a previous study reported no difference in
local or global efficiency in heroin dependence (Jiang
et al. 2013a). Thus, application of these methods to the
study of abstinent AD and poly-drug SD is limited, and
the existing literature remains inconsistent.
In the current study, we examined the effect of nal-
trexone on global network properties, namely, local and
global efficiency, assessing their relationship with addic-
tive substance exposure. We also assessed region-to-
region connectivity in a data-driven manner with
network-based statistics (NBS) (Zalesky, Fornito, &
Bullmore 2010) in individuals with AD, poly-drug SD
and healthy controls. If aberrant network organization
is observed in AD and poly-drug SD, restoration of such
topological properties may be one mechanism by which
naltrexone exerts its effects.
MATERIALS AND METHODS
Participants
Details of study design and procedures are reported else-
where (Paterson et al. 2015). Inclusion criteria included
individuals who met DSM-IV criteria for current or prior
AD, or another substance of dependence (e.g. amphet-
amines, benzodiazepines, cocaine and opiates) (poly-drug
SD). Participants were abstinent, and there was no upper
limit for abstinence. Abstinence was determined through
clinical interviews during the baseline session and by
using urine and alcohol breath test on each day of test-
ing. Participants were not undergoing pharmacological
treatment. All participants were aged 21 to 64 years.
The healthy control group had no previous history of sub-
stance abuse, as assessed using the Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST) (Group
WAW 2002) and timeline follow-back. The healthy con-
trol group was matched for age, gender and smoking
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status where possible. All participants were required to
provide a negative breath alcohol test and a negative
urine sample (screening for the presence of amphet-
amines, benzodiazepines, cocaine and opiates) on experi-
mental days. Participants were asked to refrain from
cannabis use for the 7 days prior to testing. Positive re-
sults for cannabinoids were accepted; however, because
of the long half-life of metabolites, so long as the partici-
pant was not under intoxication or withdrawal. For the
alcohol group, prior dependence on any other substance
was exclusionary. Exclusion criteria included are as fol-
lows: current use of regular prescription or non-
prescription medication that would interfere with study
integrity or subject safety; current primary axis I diagno-
sis; current or past history of enduring severe mental
illness; current or past psychiatric history that contrain-
dicated participation; history or current significant
neurological diagnosis that may have influenced analysis
or results; claustrophobia or unable to lie in the MRI
scanner for 90 minutes; a cardiac pacemaker, other elec-
tronic device or other MRI contraindication, including
pregnancy, as assessed by a standard pre-MRI question-
naire. Secondary or lifetime history of depression or
anxiety was permitted in both SD and healthy volunteers,
as these are common comorbidities in the former.
Procedure
All participants underwent a baseline session followed by
two study sessions in which clinical, cognitive and neuro-
imaging tests were completed under either placebo or
naltrexone, in counterbalanced order. The drug was ad-
ministered 2 hours before each scan. A 50-mg oral dose
of naltrexone (manufactured by Bristol-Myers Squibb
Pharmaceutical Limited, UK) provided as per the British
National Formulary was administered per participant.
Subjects participated in resting state functional MRI,
which was always first, and followed by three task-based
functional MRI scans.We examined individuals who com-
pleted both study sessions, which were counterbalanced,
and there were no participant dropouts between these
sessions (36 healthy volunteers [17 placebo first,
Imperial/Cambridge/Manchester (ICM) = 13/12/11]; 36
poly-drug SD (19 placebo first, ICM = 12/13/11); 21 AD
(12 placebo first, ICM = 10/6/5)). Please see Supporting
Information for further details of procedure and assess-
ments taken.
Resting State Functional MRI
Acquisition and Processing
Data acquisition procedures are reported elsewhere
(McGonigle et al. 2016). Briefly, data were collected
from three centres in the United Kingdom (Imperial
College London and University of Cambridge with 3T
Siemens Tim Trio with a Siemens 32 channel head coil,
and Salford Royal NHS Foundation Trust, Manchester
using 3T Philips Achieva with an eight-element SENSE
head coil). A recent report (McGonigle et al. 2016) dem-
onstrated no differences between centres for neuroimag-
ing results during task performance, using the exact
same data acquisition sequences and processing in
healthy volunteers. Please see Supporting Information
for further details.
Resting state functional MRI data were collected for
360 seconds from all participants with eyes closed. Par-
ticipants were asked to think of nothing in particular.
Data were pre-processed using speedypp.py as part of
the fMRI signal processing toolbox v1.0, which draws
upon modules from afni toolbox (http://afni.nimh.nih.
gov). As motion significantly affects connectivity mea-
sures during resting state fMRI, motion parameters and
derivatives and signal from cerebrospinal fluid were
regressed out. Signals with high change in BOLD signal
from volume to volume, i.e. dvars> 2, may not have been
sufficiently corrected for motion (Power et al. 2012), and
these subjects were removed in a secondary, more strin-
gent analysis, resulting in removal of three AD, 10 poly-
drug SD and eight HV participants. Dvars were not signif-
icantly different between groups (P > 0.05). Data were
zero-padded, despiked and slice-time corrected. Anatomi-
cal and functional images were co-registered and normal-
ized to a Montreal Neurological Institute (MNI152)
template.
Graph Theory Analysis
We extracted regional mean fMRI time series for 90 re-
gions of interest (ROI) in the Anatomical Automatic La-
beling template (Tzourio-Mazoyer et al. 2002) for each
individual. Each regional mean time series was
decomposed into wavelet coefficients at four scales using
the maximum overlap discrete wavelet transform, a
time-frequency transformation. We used the scale 2
wavelet correlation matrices, which represent function-
ally relevant signals in the frequency range of
0.061~0.125 Hz, in line with previous reports assessing
network efficiency measures (Achard & Bullmore
2007). We constructed a whole brain ROI-to-ROI correla-
tion matrix using pairwise region-to-region correlations
between coefficients, as described in a previous study
(Achard & Bullmore 2007). The functional connectivity
weights were binarized with the density threshold of 5
percent to control network density between subjects
(Achard & Bullmore 2007) and reduce the possibility of
spurious connections, thus being the most parsimonious
threshold generating the core connectivity of the
network.
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Whole Brain Network Characteristics
Local and global efficiency in the binarized graph were
computed as described in previous literature (Meunier
et al. 2009; Rubinov & Sporns 2010). Local and global
efficiency measures were entered into repeated measures
ANOVA assessing group as a between-subject factor and
drug as a within-subject factor. Comparisons were made
using placebo, as a drug-control session; however, the
baseline session was additionally assessed to examine var-
iability across sessions for each subject group. The AD
and poly-drug SD groups were then separately compared
with the HV group. Local and global efficiency were cor-
related with drug and alcohol exposure using Pearson’s
correlation. Outcomes of P < 0.05 were considered sig-
nificant. Nodal efficiency was examined on an explor-
atory basis for significant main findings.
Network-based Statistics
Group comparisons in region-to-region connectivity were
assessed using NBS Toolbox (Zalesky et al. 2010), for
MATLAB (The MathWorks, Inc., Natick, Massachusetts,
United States). Group differences are tested at every con-
nection within the connectivity matrices (inter-regional
correlation in BOLD activity) using an initial threshold
of T > 3 as described in the work of Zalesky et al
(2010). NBS identified the interconnected subnetwork
Table 1 Demographic and questionnaire data.
n Age Sex (female) BDI-II-total STAI-S-total STAI-T-total
Poly-drug SD 36 38.167 7.000 10.889 34.194 40.972
7.636 6.927 9.674 12.263
AD 21 45.381 4.000 9.905 33.333 40.905
8.789 9.534 11.284 12.136
HV 36 40.833 8.000 3.861 26.472 29.944
8.674 4.486 6.759 7.917
P 0.011 <0.001 0.001 <0.001
Alcohol
abstinence
Cocaine
abstinence
Opiate
abstinence
Alcohol
exposure
Cocaine
exposure
Opiate
exposure
Poly-drug SD 18.157 31.493 42.683 9.903 6.153 7.867
37.483 33.750 59.684 9.260 5.399 7.234
AD 13.417 28.955 15.875 18.714 0.636 0
18.693 24.942 19.976 8.655 1.433 0
HV 0.317 120.600 NA 1.176 0 0
0.924 140.335 NA 3.157 0 0
Age first used
cocaine
Age first used
opiates
Age used alcohol
regularly
Age used cocaine
regularly
Age used opiates
regularly
Poly-drug SD 19.833 20.767 15.559 23.594 21.750
4.326 6.038 3.910 6.293 3.904
AD 31.455 42.000 16.524 33.000
10.182 7.071 3.558 9.592
HV 25.000 NA 18.485 Na NA
2.739 NA 3.684 NA NA
Smokers
(current/previous/non)
Cigarettes
number per day
Pack years
Poly-drug SD 08/04/24 15.964 19.541
8.558 14.261
AD 14/04/03 17.179 26.535
7.324 18.404
HV 19/04/13 9.637 14.667
6.776 12.623
p 0.004 0.010 0.052
Mean and standard deviation is reported. Abstinence is reported in months. SD, substance dependence; AD, alcohol dependence; HV, healthy volunteer;
N, number; BDI, Beck Depression Inventory; STAI, state–trait anxiety index; NA, not applicable.
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consisting of suprathreshold edges (T > 3 in group differ-
ence). The size of the interconnected subnetwork (i.e. the
number of interconnected suprathreshold edges) was
used to calculate a family-wise error corrected P-value
using 10 000 permutation tests (P < 0.05, family-wise
error corrected). In other words, NBS identified an inter-
connected subnetwork of altered connectivity with a
cluster-level corrected P-values using network cluster
size (the number of interconnected suprathreshold
edges). AD and poly-drug SD were separately compared
with HV. AD and poly-drug SD were compared with each
other on an exploratory basis.
RESULTS
Participant Characteristics
Demographic and questionnaire data are presented in
Table 1. Of the poly-drug SD, 12 met criteria for all of al-
cohol, cocaine and opiate dependence, eight for alcohol
and cocaine, three for alcohol and opiates and five for co-
caine or opiates only. Poly-drug SD were
31.493 ± 33.750 months abstinent from cocaine (range
0.5–132) and 19.833 ± 4.326 age of first use; were
18.157 ± 37.483 months abstinent from alcohol (range:
0.5–204); and were 42.683 ± 59.684 months abstinent
from opiates (range: 1.5–276) and age of first opiate use
was 20.767 ± 6.038. Healthy volunteers and AD had no
history of opiate use. Five healthy volunteers and 10 AD
had a history of cocaine use without meeting criteria
for dependence. AD participants were abstinent from al-
cohol 13.417 ± 18.693 months (range: 0.5–79), and
age of regular alcohol use was 16.524 ± 3.558, and
abstinent from cocaine 28.955 ± 24.942 months (range:
1.75–72) and age of first use of cocaine was
31.455 ± 10.182. Healthy volunteers were
0.317 ± 0.924 months abstinent from alcohol (range:
0–0.75) and 120.6 ± 140.225 from cocaine (range: 3–
360). Further details including smoking information are
presented in Table 1.
Whole Brain Network Characteristics
We examined local and global efficiency of neural net-
works in AD, poly-drug SD and healthy volunteers (HV)
comparing between naltrexone and placebo as a drug
control. There was a significant effect of drug
(F(1,90) = 7.977, P = 0.006), and a significant
drug × group interaction (F(2,90) = 3.672, P = 0.029).
There was no effect of group (F(1,90) = 2.306,
P = 0.106). Results remained significant when 21 partic-
ipants were removed based on a stringent motion thresh-
old (without 3 AD, 10 poly-drug SD and 8 HV: effect of
naltrexone, P = 0.006; interaction, P = 0.041). Results
remained significant when HV with any prior drug use
were removed from the analysis and when opiate or co-
caine dependence only was removed (i.e. ‘pure’ HV and
poly-drug dependence). Analysis of global efficiency
showed no group, naltrexone effects or interactions.
For the investigation of the effects on local efficiency
further, the whole AD and poly-drug SD were separately
compared with the whole HV group. For the AD compar-
ison with healthy volunteers, there was a main effect of
drug (F(1,55) = 5.610, P = 0.021) in which naltrexone
was associated with lower local efficiency. There was also
Figure 1 Neural network local effi-
ciency under placebo and naltrexone.
Local efficiency was captured based
on a whole brain ROI-to-ROI correla-
tion coefficient matrix, binarized with
a 5 percent density threshold and is
plotted for naltrexone and placebo
for alcohol-dependent (Alc, unbro-
ken line), poly-substance-dependent
(Poly, broken line) and healthy volun-
teers (HV, dotted line). For the com-
parison between drugs, there was a
significant effect of naltrexone
(P = 0.006), a significant drug × group
interaction (P = 0.029) and no effect
of group (P = 0.106)
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a significant group × drug interaction (F(1,55) = 6.836,
P = 0.012) (Fig. 1) in which naltrexone decreased local
efficiency to a greater extent in AD, bringing local effi-
ciency to the same level as healthy volunteers. For the ex-
amination of which regions contributed to this difference
in local efficiency, nodal efficiency for individual nodes
was compared on an exploratory basis. AD had increased
local efficiency of bilateral rectus gyrus (medial
orbitofrontal cortex), right supplementary motor area,
left middle frontal gyrus, left middle occipital gyrus, left
parahippocampal gyrus and right olfactory bulb nodes
during placebo and increased local efficiency in the mid-
dle cingulate gyrus only during naltrexone; however,
these findings did not survive Bonferroni correction for
multiple comparisons (Supporting Information Table
S1). The main effects were also replicated in an analysis
with 21 participants removed based on stringent motion
thresholds (naltrexone effect, P = 0.034; interaction,
P = 0.015). There was no main effect of group
(F(1,55) = 1.399, P = 0.242).
For the poly-drug SD comparison with healthy volun-
teers, there was a main effect of group (F(1,70) = 4.259,
P = 0.043) in which poly-drug SD was associated with
higher local efficiency, suggesting more segregated and
clustered information processing. There was no main
effect of naltrexone (F(1,70) = 0.845, P = 0.361) or inter-
action (F(1,70) = 1.563, P = 0.215). Removing 10 poly-
drug SD and eight HV individuals from this analysis based
on stringent motion criteria resulted in a lack of signifi-
cant group effect (P = 0.159).
Baseline local efficiency was also computed and illus-
trated in Supporting Information Fig. S1. Across the three
sessions (baseline, placebo and naltrexone), there was no
difference in local efficiency in HV (F(2,33) = 0.486,
P = 0.619) or poly-drug SD subjects (F(2,33) = 2.182,
P = 0.129). However, there was a significant difference
across sessions in AD (F(2,17) = 5.439, P = 0.015,
Supporting Information Fig. S1), in which naltrexone re-
duced or ‘normalized’ local efficiency in this group only.
Clinical Relationship
We further examined the relationship between
drug/addictive substance exposure and local and global
efficiency on placebo. Local efficiency positively correlated
with opiate exposure (R = 0.365, P = 0.044) and cocaine
exposure at trend level (R = 0.295, P = 0.058) across AD
and poly-drug SD groups (Fig. 2). While there were no
group differences in global efficiency, we found that
across all groups including healthy volunteers it
Figure 2 Correlations between neural network efficiency and drug exposure. Top: local efficiency is plotted against opiate exposure
(R = 0.365, P = 0.044) and cocaine exposure (R = 0.295, P = 0.058). Bottom: global efficiency plotted against alcohol exposure and age
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negatively correlated with alcohol exposure
(R = 0.210, P = 0.049) and age (R = 0.292,
P = 0.005) (Fig. 2). When controlling for age, there
was no significant correlation between global efficiency
and alcohol exposure, suggesting that age might have
been the contributing factor to reduced global efficiency
as the AD group was slightly older.
Local efficiency was not correlated with age, length of
abstinence from alcohol across AD and poly-drug SD
groups (P > 0.6) or from cocaine (P > 0.1) or opiates
(P > 0.8) in the poly-drug SD group. As levels of depres-
sive and anxiety symptoms were higher in AD and poly-
drug SD groups (Table 1), we examined whether there
was any relationship between these measures and net-
work efficiency. BDI-II scores for depression and state
and trait STAI anxiety scores were not significantly corre-
lated with local or global efficiency on placebo or naltrex-
one (P > 0.1). Please see Supplementary materials for
further data.
Network-based Statistics
In order to understand which regions might be driving
this disruption in local efficiency, we examined the sub-
network of altered functional connectivity using
network-based statistical analysis. AD and poly-drug SD
were separately compared with HV. NBS identified a large
network of significantly decreased functional connectivity
in AD compared with HV (P = 0.001, network-based, 69
nodes, 373 edges) (Fig. 3, Supporting Information Table
S2) during placebo. The network cluster included many
regions, but regions showing the greatest reduction in
connectivity were temporal, inferior frontal and supple-
mentary motor area nodes (depicted as larger nodes in
Fig. 3). There was no significantly increased functional
connectivity in AD compared with HV with NBS. There
was no significant difference between the poly-drug SD
group and HVas measured by NBS (P > 0.1). The reduc-
tion in network connectivity in AD compared with HV
was replicated in the baseline session (P = 0.030, 40
nodes, 53 edges, Supporting Information Table S4 and
Fig. S2), although the network cluster included different
regions. The lack of difference between poly-drug SD
and HV was also replicated at baseline (P > 0.05). On
an exploratory basis, we also directly compared between
the poly-drug SD and AD groups. AD had reduced net-
work connectivity compared with poly-drug SD in a net-
work that comprised of frontal regions and para-
hippocampus (P = 0.010, 61 nodes, 111 edges, Fig. 4
and Supporting Information Table S3).
DISCUSSION
We examined the effects of a single dose of the MOR an-
tagonist naltrexone in AD and poly-drug SD subjects.
Figure 3 Network cluster of reduced functional connectivity in alcohol-dependent subjects. Network-based statistics demonstrated a large
network of reduced connectivity in alcohol-dependent compared with healthy subjects. Node size indicates number of connections with re-
duced functional connectivity. The largest nodes are annotated. Inf, inferior; SMA, supplementary motor area; L, left; R, right
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AD had elevated local efficiency across the whole neural
network indicating more isolated and clustered informa-
tion processing. Naltrexone decreased local efficiency in
AD individuals, to the same levels as healthy volunteers.
Local efficiency in poly-drug SD was not affected by nal-
trexone and was positively associated with exposure to
drugs of abuse (opiate exposure and a trend for cocaine
exposure). That naltrexone normalizes local efficiency in
AD but no poly-drug SD may help determine likely re-
spondents to pharmacotherapy and the current imaging
techniques may highlight potential responders.
Naltrexone seemed to be effective at reducing local
efficiency in the AD group but had no effect in poly-drug
SD subjects. Indeed, poly-drug SD subjects showed no
difference in local efficiency across the three sessions,
although they did show heightened local efficiency dur-
ing placebo. Interpretation of these findings is limited by
the comorbidity within this group, and we caution that
further investigation of local efficiency in poly-drug SD
is necessary. For example, heroin-dependent individuals
show a shift to a more random network (Jiang et al.
2013b), but cocaine-dependent individuals show reduced
local efficiency (Wang et al. 2015). However, the current
study does clarify the effect of naltrexone on local effi-
ciency in AD subjects. While healthy individuals demon-
strated stable levels of local efficiency throughout the
experiment, AD showed heighted local efficiency during
baseline and placebo that was significantly reduced un-
der naltrexone.
The higher local efficiency observed suggests elevated
clustering of functionally related regions (Sporns et al.
2004). This means that information processing within
certain neural networks is stronger, with less cross-talk
between distinct functional processes. This clustering of
connections suggests hyperactive intermediate signalling
(rather than long-range signalling) in the network,
perturbing the capacity for more global neural coopera-
tion or wider cortical interactions (Sporns et al. 2004).
Higher local efficiency may also suggest higher likelihood
of closed feedback loops and enhanced reciprocity of con-
nections, meaning that information is not dispersed and
processed across networks but remains closed off in a spe-
cific network model (Sporns et al. 2004). Thus, informa-
tion process is more segregated and clustered. Higher
segregation of network communication may relate to less
flexible information processing, a functional segregation
and behavioural rigidity that is observed in addiction.
The medial orbitofrontal cortex and supplementary
motor area were particularly implicated as being more
segregated. Indeed, AD individuals have reduced volume
and cortical thickness of the orbitofrontal cortex (Durazzo
et al. 2011) that predicts future relapse (Beck et al. 2012)
and simultaneously show heightened drug cue reactivity
in this region (Chase et al. 2011; Kuhn & Gallinat 2011;
Engelmann et al. 2012), which is modulated by gene type
during naltrexone (OPRM1 gene G allele carriers)
(Kareken et al. 2010). Similarly, supplementary motor
area volume is reduced in binge drinkers (Kvamme et al.
Figure 4 Network cluster of reduced functional connectivity in alcohol-dependent subjects compared with poly-drug substance-dependent
subjects. Network-based statistics demonstrated a network of reduced connectivity in alcohol-dependent subjects compared with poly-drug
SD subjects. Node size indicates number of connections with reduced functional connectivity. The largest nodes are annotated. Sup, superior;
Med, medial; Inf, inferior; L, left; R, right
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2016), and AD subjects show increased SMA activity
related to impulsivity (Claus, Kiehl, & Hutchison 2011).
The current demonstration of network topology changes
in these regions may reflect reduced long-range connec-
tions but more local neighbouring connections that coin-
cide with reduced volumes but increased functional
responses to drug or salient cues.
While global network measures like local efficiency,
and region-to-region connectivity measures are quite dis-
tinct, one might be used theoretically to inform the other.
In the current paper, NBS were used to examine which
nodes of the network might be driving the finding of
heightened local efficiency in the AD group. AD demon-
strated a significant reduction in connectivity in a net-
work involving frontal and temporal and supplementary
motor regions, compared with HV. This might suggest
that frontal and temporal regions show enhanced cluster-
ing and segregation of information processing that would
simultaneously contribute to reduced functional connec-
tivity and higher global local efficiency. Furthermore, the
decreased functional connectivity in AD revealed by NBS
may be long-range, cross-module connections. A reduc-
tion in long-range connections is associated with more
isolated local circuits, making circuit modules highly
clustered, thereby increasing local efficiency. Reduced
neural functional connectivity has been previously dem-
onstrated in this group, particularly of the left executive
control network (including parietal, dorsolateral and me-
dial prefrontal cortex), i.e. associated with impaired be-
havioural control and alcohol use severity (Weiland
et al. 2014). Furthermore, in young adults at high risk
for AD, enhanced task-related functional connectivity
among nucleus accumbens, sensorimotor cortex and
precuneus has been associated with alcohol use severity
(Weiland et al. 2014). These findings suggest a reduced
baseline state and hyperactive task-related connectivity
of particular nodes may relate to more severe alcohol use.
There have been several characterizations of the ef-
fects of stimulant and opiate SD on seed-based functional
connectivity. Chronic heroin users show disruption of
both cortical (prefrontal cortex, anterior cingulate and
insula) and subcortical (ventral striatum, amygdala and
hippocampus) connectivity patterns (Liu et al. 2010;
Yuan et al. 2010; Jiang et al. 2013b), consistent with def-
icits in executive decision making (Verdejo-Garcia,
Perales, & Perez-Garcia 2007; Verdejo-Garcia & Perez-
Garcia 2007) and reward-related behavioural control
(Harris & Aston-Jones 2003) in this group. Similarly,
cocaine-dependent individuals have reduced functional
connectivity of widespread prefrontal, premotor and pari-
etal networks associated with attentional deficits (see also
(Gu et al. 2010; Konova et al. 2013)). However, few stud-
ies have focused on poly-drug SD, and as mentioned, co-
morbidity might be an issue because of distinct effects of
each substance of abuse on topological or functional net-
work properties. The current findings do suggest that
prolonged drug exposure in the poly-drug SD group, in
particular exposure to opiates, is associated with elevated
local efficiency of neural networks. That local efficiency is
related to opiate and cocaine use, but no alcohol suggests
local efficiency as a potential premorbid risk factor in AD
that can be ameliorated by naltrexone whereas naltrex-
one does not modulate local efficiency in poly-drug SD.
In contrast with a previous study of local and global ef-
ficiency in cocaine-dependent individuals (Wang et al.
2015), we did not find group differences in global effi-
ciency. Inconsistencies between the findings of the current
and previous studies may relate to the presentation of
poly-drug use rather than single-drug dependence, or
relate to abstinence. The previous study showing reduced
global efficiency in cocaine-dependent individuals included
individuals with 4 to 8 days of abstinence rather than the
current criteria of at least 4 weeks. Further studies are
clearly required to elucidate the effects of substance and
abstinence on large-scale network efficiency measures.
Limitations of the current study include the comorbid-
ity within groups, e.g. nicotine use or dependence and
high levels of depression and anxiety. This however is a
fair representation of the substance and alcohol-
dependent population as a whole. While the current
study uses data from three separate centres, this can be
considered a benefit rather than a limitation as it demon-
strates, along with a previous report (McGonigle et al.
2016), that data can be integrated effectively across sites,
a feature that is particularly important for large studies
examining groups with high attrition rates.
We have thus provided insight into the effects (or lack
thereof) of a well-established psychopharmaceutical agent,
naltrexone, on large-scale network dynamics in AD and
poly-drug SD subjects. Differentiating drug efficacy profiles
for distinct groups of patients is crucial for the develop-
ment of more effective and targeted treatments.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Data S1 Table S1. Regions with reduced nodal efficiency
in alcohol dependent (Alc) individuals compared to
healthy volunteers (HV). Local efficiency for each node
was calculated and compared between groups during
placebo and naltrexone. Mean and standard error of the
mean (s.e.m) are demonstrated and P-values for both un-
corrected and Bonferroni correction for multiple compar-
isons tests are displayed. Left, L; Right, R. Table S2.
Regions demonstrating reduced functional connectivity
in alcohol dependent subjects compared to healthy vol-
unteers. Network based statistics revealed a significant
cluster of reduced functional connectivity including 69
nodes and 373 edges. The number indicates the number
of connections included in the significantly reduced clus-
ter. Temporal and inferior frontal regions seemed to show
the highest reduction in network connectivity. Left, L;
Right, R. Table S3. Regions demonstrating reduced func-
tional connectivity in alcohol dependent subjects com-
pared to poly-drug dependent subjects. The number
indicates the number of connections included in the sig-
nificantly reduced cluster. Frontal regions show the
highest reduction in network connectivity. Left, L; Right,
R. Table S4. Regions demonstrating reduced functional
connectivity in alcohol dependent subjects compared to
healthy volunteers during baseline session. The number
indicates the number of connections included in the sig-
nificantly reduced cluster. Left, L; Right, R. Table S5. Re-
gions demonstrating reduced functional connectivity in
alcohol dependent subjects compared to healthy volun-
teers during naltrexone. The number indicates the num-
ber of connections included in the significantly reduced
cluster. Left, L; Right, R.
Figure S1 Neural network local efficiency under naltrex-
one. Local efficiency was captured based on a whole brain
ROI-to-ROI correlation coefficient matrix, binarized with
a 5 percent density threshold and is plotted for baseline,
naltrexone and placebo for alcohol dependent (Alc, un-
broken line), poly-substance dependent (Poly, broken
line) and healthy volunteers (HV, dotted line). There
was no difference in local efficiency across sessions in
HV or Polysubjects. There was a significant difference
across sessions in the Alc group, in which local efficiency
was significantly reduced by naltrexone.
Figure S2 Network cluster of reduced functional connec-
tivity in alcohol dependent (AD) subjects during baseline
session. Network based statistics demonstrated a large
network of reduced connectivity in AD compared with
healthy subjects. Node size indicates number of connec-
tions with reduced functional connectivity. The largest
nodes are annotated.
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